Clearmind Medicine AI Stock Analysis
Clearmind Medicine (CWY1) AI Stock Analysis
Clearmind Medicine
(Frankfurt:CWY1)
No summary available
Clearmind Medicine (CWY1) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 1.33M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 0.32
- Revenue Growth
- ―
- EPS Growth
- 75.61%
- Country
- Germany
- Employees
- 4
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Clearmind Medicine Business Overview & Revenue Model
Company Description
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lac...
Clearmind Medicine Peers Comparison
Overall Rating
ENVB48Neutral
NEUP48Neutral
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:CWY1 | Clearmind Medicine Inc. | 180.48 | -348.80 | -65.90% | |
| ENVB | Enveric Biosciences, Inc. | 1.35 | -4.41 | -76.56% | |
| SILO | Silo Pharma Inc | 1.71 | -4.68 | -73.24% | |
| PBM | Psyence Biomedical Ltd. | 2.97 | -6.47 | -68.53% | |
| NEUP | Neuphoria Therapeutics Inc. | 2.35 | -2.08 | -46.95% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
